CARA THERAPEUTICS, INC. (NASDAQ:CARA) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
Cara Therapeutics, Inc. (the “Company”) issued a press release on August3, 2017 announcing its financial results for the second quarter ended June30, 2017.A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.
The information furnished to this Item 2.02 shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, we undertake no duty or obligation to publicly update or revise the information so furnished.
| Item 2.02. | Financial Statements and Exhibits. |
| ExhibitNo. | Description |
| 99.1 | Press Release dated August3, 2017 |
Cara Therapeutics, Inc. ExhibitEX-99.1 2 d436056dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Cara Therapeutics Reports Second Quarter 2017 Financial Results – Conference call today at 4:30 p.m. ET – STAMFORD,…To view the full exhibit click here
About CARA THERAPEUTICS, INC. (NASDAQ:CARA)
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company’s I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company’s CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.
